Immunocore Holdings plc
For the period ended Mar 31, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 7, 2025
IMCR$32.38+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows for the
Condensed Consolidated Statements of Cash Flows
(Unaudited) (In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net income (loss) | $5,023 | $(24,436) |
| Adjustments for: | ||
| Share-based compensation expense | 9,489 | 8,964 |
| Depreciation | 854 | 1,011 |
| Unrealized foreign exchange (gains) losses, net | (2,907) | 1,304 |
| Unrealized gains on marketable securities | (5,469) | — |
| Non-cash lease expense | 546 | 432 |
| Other | 509 | (2) |
| Changes in assets and liabilities: | ||
| Decrease (increase) in accounts receivable | 836 | (6,198) |
| Increase in prepayments and other current assets | (28) | (1,819) |
| Increase (decrease) in accounts payable | 3,342 | (2,320) |
| (Decrease) increase in accrued expenses | (10,943) | 19,169 |
| Increase (decrease) in operating lease liabilities | 756 | (490) |
| Increase in other operating assets | (1,573) | (1,395) |
| Increase in other operating liabilities | — | 1,193 |
| Net cash provided by (used in) operating activities | 435 | (4,587) |
| Cash flows from investing activities | ||
| Proceeds from sale of marketable securities | 10,000 | — |
| Purchase of property and equipment | (298) | (430) |
| Net cash provided by (used in) investing activities | 9,702 | (430) |
| Cash flows from financing activities | ||
| Proceeds from exercise of share options | 2,551 | 5,754 |
| Proceeds from issue of convertible loan notes | — | 402,500 |
| Payments for debt issuance costs | — | (12,242) |
| Net cash provided by financing activities | 2,551 | 396,012 |
| Increase in net cash and cash equivalents | 12,688 | 390,995 |
| Net foreign exchange difference on cash held | 8,426 | (800) |
| Cash and cash equivalents at beginning of period | 455,731 | 442,626 |
| Cash and cash equivalents at end of period | 476,845 | 832,821 |
| Supplemental disclosure of cash flow and non-cash information | ||
| Cash (paid) received for interest, net | $(5,031) | $5,141 |
| Cash paid for income taxes, net | $(32) | $(140) |
| Debt issuance costs in accrued expenses and other current liabilities | $— | $(1,116) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.